Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Sees Significant Drop in Short Interest

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the target of a large decrease in short interest during the month of February. As of February 13th, there was short interest totaling 122,516 shares, a decrease of 15.2% from the January 29th total of 144,490 shares. Approximately 7.7% of the shares of the stock are sold short. Based on an average trading volume of 108,559 shares, the days-to-cover ratio is presently 1.1 days. Based on an average trading volume of 108,559 shares, the days-to-cover ratio is presently 1.1 days. Approximately 7.7% of the shares of the stock are sold short.

Hedge Funds Weigh In On Cardio Diagnostics

An institutional investor recently raised its position in Cardio Diagnostics stock. DRW Securities LLC increased its position in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) by 122.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,463 shares of the company’s stock after buying an additional 22,298 shares during the quarter. DRW Securities LLC owned 2.21% of Cardio Diagnostics worth $110,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 8.06% of the stock is currently owned by institutional investors and hedge funds.

Cardio Diagnostics Stock Up 2.1%

CDIO opened at $5.37 on Friday. The business’s fifty day simple moving average is $2.49 and its 200 day simple moving average is $3.29. Cardio Diagnostics has a 52 week low of $0.97 and a 52 week high of $17.39. The stock has a market cap of $9.83 million, a PE ratio of -1.44 and a beta of 2.28.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardio Diagnostics in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cardio Diagnostics has an average rating of “Sell”.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.